Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study

摘要

In the large observational multicenter Unicancer-ESME database, adjusted OS was longer in first line metastatic breast cancer patients receiving paclitaxel and bevacizumab than in those receiving paclitaxel alone (HR 0.672, 95%CI 0.601-0.752; median OS 27.7 vs 19.8 months). Despite robust methodology, real-life data are exposed to potential biases and interpretation requires caution.Bevacizumab combined with paclitaxel as first-line chemotherapy for patients with HER2-negative metastatic breast cancer (MBC) has led to mixed results in randomized trials, with an improvement in progression-free survival (PFS) but no statistically significant overall survival (OS) benefit. Real-life data could help in assessing the value of this combination.